DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, ...

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...

The company will unveil Dexcom Smart Basal*, a new integrated titration module designed to make basal insulin initiation and management easier† for users, which is currently under FDA and CE mark ...

DexCom has partnered with Google Life Sciences to develop the next generation of DexCom's CGM -- a device that is "the size of a dime", less expensive than current CGMs, and that the companies hope ...

Oct 24 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat Wall Street estimates for third-quarter revenue and profit on Thursday, helped by resilient demand for its continuous ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Investors considering a purchase of DexCom Inc (Symbol: DXCM) stock, but tentative about paying the going market price of $72.64/share, might benefit from considering selling puts among the ...

VIENNA--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose ...